£500K
The health tech company surpassed £500k on Crowdcube with backing from more than 100 investors.
.png)
Digostics builds an at-home oral glucose tolerance test for diabetes detection.
Digostics develops GTT at home, an oral glucose intolerance test designed to replace clinic visits. The CE marked platform supports diabetes screening for patients in the UK and international markets.
Cash at bank
Net current assets
Total assets less current liabilities
Net assets
Shareholders' funds
Fixed assets
Cash, assets and headcount from Digostics's latest Companies House filing — with year-on-year movement, free with a Winfred account.
James Jackson
CEO and Founder
The health tech company surpassed £500k on Crowdcube with backing from more than 100 investors.